Citius Pharmaceuticals (CTXR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CTXR Citius Pharmaceuticals

Watchlist

0.1338
-0.0313-18.96%

Close Nov 22 16:00 ET

0.1346
+0.0008+0.60%

Post 19:57 ET

25.85MMarket Cap-557P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Citius Pharmaceuticals To Carry Out 1-for-25 Reverse Stock Split On November 26th, 2024
Moomoo NewsNov 22 19:40 ET
D. Boral Capital Downgrades Citius Pharmaceuticals(CTXR.US) to Hold Rating
Moomoo NewsNov 22 16:32 ET · Ratings
Citius Pharmaceuticals Cut to Hold From Buy by D. Boral Capital
Dow JonesNov 22 16:28 ET · Ratings
Sector Update: Health Care Stocks Rise Friday Afternoon
MT NewswiresNov 22 13:57 ET
Express News | Citius Pharmaceuticals Inc - Reverse Stock Split Effective at 5:00 PM Et on Nov 25, 2024
ReutersNov 22 09:00 ET
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split >CTXR
Dow JonesNov 22 09:00 ET

Comments

Stock_Drift

Nov 22 10:10

R/S 11/25/24

$Citius Pharmaceuticals (CTXR.US)$

萬軍無兵策天鳳

Nov 16 00:06

$Citius Pharmaceuticals (CTXR.US)$ 增发时新闻里是这么写的“Citius Pharma's ability to regain compliance with and continue to meet Nasdaq's continued listing standards; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA”

Stock_Drift

Nov 15 12:55

$Citius Pharmaceuticals (CTXR.US)$

Buzz killington

Nov 14 09:50

$Citius Pharmaceuticals (CTXR.US)$ lmao what a scam piece of shit they go and have the scam institutions put out a bunch of high ratings just to crash it on everyone buying in good thing I seen the manipulation in the book and got out with only a 88 dollar loss could have been thousands

Teddy123

Nov 14 05:50

Has until 3 Dec to go to 1

$Citius Pharmaceuticals (CTXR.US)$
0
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing;

As previously disclosed, on September 12, 2023, Citius Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share, for the prior 30 cons...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CTXR Citius Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target